PROF vs. SMLR, EMBC, CBLL, BVS, BBNX, AVNS, AXGN, KIDS, BFLY, and DCTH
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include Semler Scientific (SMLR), Embecta (EMBC), CeriBell (CBLL), Bioventus (BVS), Beta Bionics (BBNX), Avanos Medical (AVNS), AxoGen (AXGN), OrthoPediatrics (KIDS), Butterfly Network (BFLY), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.
Profound Medical vs. Its Competitors
Semler Scientific (NASDAQ:SMLR) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.
Semler Scientific has a net margin of -60.69% compared to Profound Medical's net margin of -269.35%. Semler Scientific's return on equity of 19.75% beat Profound Medical's return on equity.
49.4% of Semler Scientific shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 30.2% of Semler Scientific shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Semler Scientific had 6 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for Semler Scientific and 1 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 beat Semler Scientific's score of 0.47 indicating that Profound Medical is being referred to more favorably in the news media.
Semler Scientific currently has a consensus price target of $89.00, suggesting a potential upside of 115.81%. Profound Medical has a consensus price target of $11.00, suggesting a potential upside of 95.04%. Given Semler Scientific's stronger consensus rating and higher possible upside, equities analysts plainly believe Semler Scientific is more favorable than Profound Medical.
Semler Scientific has higher revenue and earnings than Profound Medical. Semler Scientific is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
Semler Scientific has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
Summary
Semler Scientific beats Profound Medical on 13 of the 16 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
This page (NASDAQ:PROF) was last updated on 7/18/2025 by MarketBeat.com Staff
